Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder. Tyrosine kinase inhibitors (TKIs) are the standard treatments for CML, but a number of patients fail to respond effectively due to gene mutations. Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, has been shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ying, Liu, Ling-Ling, Liu, Shou-Sheng, Fang, Zhi-Gang, Zou, Yong, Deng, Xu-Bin, Long, Zi-Jie, Liu, Quentin, Lin, Dong-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029099/
https://www.ncbi.nlm.nih.gov/pubmed/27645552
http://dx.doi.org/10.1186/s12967-016-1012-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029099/
https://www.ncbi.nlm.nih.gov/pubmed/27645552
http://dx.doi.org/10.1186/s12967-016-1012-8

Ejemplares similares